Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.51 |
| ▸ | NPY1R | P25929 | 7/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.51 |
| ▸ | NPY2R | P49146 | 5/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31222375 | 0.84 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31222390 | 0.83 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31222407 | 0.83 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31222395 | 0.83 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL7207977 | 0.80 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL1372389 | 0.80 | OPRD1 (0.55) | OPRD1OPRM1OPRK1 | |
| SCHEMBL7206223 | 0.79 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL1371086 | 0.79 | OPRD1 (0.57) | OPRD1OPRM1 | |
| SCHEMBL1371091 | 0.79 | OPRD1 (0.57) | OPRD1OPRM1 | |
| Acetic Acid SCHEMBL11331937 | 0.78 | OPRD1 (0.68) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051991-B1 | CARDIOPROTECTIVE COMPOUNDS | ERIBIS PHARMACEUTICALS AB (SE) | 2011-10-12 | — | — | EP | disclosed |
| US-20100093643-A1 | CARDIOPROTECTIVE COMPOUNDS | ERIBIS PHARMACEUTICALS AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093643-A1 | CARDIOPROTECTIVE COMPOUNDS | ERIBIS PHARMACEUTICALS AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2008020802-A1 | CARDIOPROTECTIVE COMPOUNDS | ERIBIS PHARMACEUTICALS AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093643-A1 | CARDIOPROTECTIVE COMPOUNDS | FABP3, NPR3, NPR1 | NPY4R 2077/4885NPY1R 1701/4885NPY5R 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.